CORRECTED - CORRECTED-Bionovo amends filing for $100 mln shelf offering

(Corrects headline and text after company clarified the filing was an amended one and part of the original shelf offering announced on June 25)

Oct 17 (Reuters) - Drug development company Bionovo Inc (BNVI.O) said in an amended regulatory filing that it may periodically sell up to $100 million of common stock and or warrants to purchase shares of common stock, or in any combination of its common stock or warrants.

The company said the offering is part of the shelf it had filed with the U.S. Securities and Exchange Commission on June 25, in which it had offered to sell 24.9 million shares to raise up to $100 million.

The company said it intends to use the proceeds for general corporate purposes, including the funding of clinical research and development programs.

Under a shelf registration filed with the U.S. Securities and Exchange Commission, a company may sell securities in one or more separate offerings with the size, price and terms to be determined at the time of sale. (Reporting by Aniruddha Basu in Bangalore)